W. Verbeeck

W. Verbeeck

Auto-generated profile, based on publicly available information

W. Verbeeck

Department of Pharmacology and Toxicology Radboudumc Nijmegen The Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2020 in European Journal of Neurology
Verified
Journal Article
Open access
PDF file
NKNick Kruijt
Nick Kruijt
LBL.R. van den Bersselaar
L.R. van den Bersselaar
EKE. J. Kamsteeg
E. J. Kamsteeg
WVW. Verbeeck
W. Verbeeck
MSM. M. J. Snoeck
M. M. J. Snoeck
NVNicol Voermans
Nicol Voermans
Background and purpose: Rhabdomyolysis is a medical emergency characterized by acute skeletal muscle breakdown with a sudden rise and subsequent fall of serum creatine kinase (CK) levels. Rhabdomyolysis events are provoked by exposure to external triggers, possibly in combination with an increased genetic susceptibility. We aimed to describe comprehensively the external triggers and potentially pathogenic genetic variants possibly implicated in increased rhabdomyolysis susceptibility.Methods: We performed a retrospective single‐center study, including a total of 1302 patients with an acute CK level exceeding 2000 IU/l.Results: Anoxia was the most frequently reported trigger (40%). A subset of 193 patients were clinically suspected of an underlying genetic disorder (recurrent episodes, a positive family history, very high or persistently increased CK levels). In 72 of these patients, an unequivocal genetic defect was identified. A total of 22 genes with pathogenic variants were identified, including 52 different variants. Of those, 11 genes have been previously associated with rhabdomyolysis (ACADVL, ANO5, CPT2, DMD, DYSF, FKRP, HADHA, PGM1, LPIN1, PYGM, RYR1). Eleven genes are probably implicated in increased susceptibility (including AGL, CAPN3, CNBP, DMPK, MAGT1, ACADM, SCN4A, SGCA, SGCG, SMPD1, TANGO2).Conclusion: These findings suggest that the spectrum of genetic susceptibility for rhabdomyolysis has not yet been completely clarified. With the increasing availability of next‐generation sequencing in a diagnostic setting, we expect that in more cases a genetic defect will be identified.